{"url_path":"/sec/mrkr/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1094038/0001104659-26-062763-index.html","accession_number":"0001104659-26-062763","cik":"0001094038","ticker":"MRKR","issuer_name":"Marker Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1094038/0001104659-26-062763-index.html","primary_entity_key":"0001094038","primary_entity_name":"Marker Therapeutics, Inc."},"word_count":82,"has_tables":true,"body_markdown":"**Item 5.         Other Information**\n\n(a)\n\nNone.\n\n(b)\n\nNone.\n\n(c)\n\n*Director and Officer Trading Plans and Arrangements*. During the quarterly period ended March 31, 2026, no director or officer of the Company adopted or terminated any contract, instruction or written plan for the purchase or sale of securities of the Company intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any “non-Rule 10b5-1 trading arrangement” (as defined in the Exchange Act).\n\n​\n\n​\n\n25\n\n[Table of Contents](#TOC)"}